Author

Y. Diao

Institution: Kelun Group (China)

Observed institution: Kelun Group (China)

OpenAlex ID: A5111355992

514O An open-label, global, first-in-human study of SKB264 in patients with locally advanced or metastatic solid tumors

2021 · J. Rodon, J. Li, et al. · Annals of Oncology · 16

380MO SKB264 (MK-2870) in previously treated hormone receptor-positive (HR+)/ HER2-negative metastatic breast cancer (mBC): Results from a phase I/II, single-arm, basket trial

2023 · Q. Ouyang, Y. Yin, et al. · Annals of Oncology · 12

LBA23 Sacituzumab tirumotecan (sac-TMT) vs investigator's choice of chemotherapy (ICC) in previously treated locally advanced or metastatic hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer (BC): Results from the randomized, multi-center phase III OptiTROP-Breast02 study

2025 · Y. Fan, H. Li, et al. · Annals of Oncology · 8

386P Exploratory analysis of patients with or without prior PD-(L)1 inhibitors in phase III OptiTROP-Breast01 study of sacituzumab tirumotecan (sac-TMT) versus chemotherapy for previously treated advanced triple-negative breast cancer (TNBC)

2024 · Y. Yin, Y. Fan, et al. · Annals of Oncology · 1

Works count: 4

Citation count: 37

H-index: 3

I10-index: 2